GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Receivables Turnover

CTOR (Citius Oncology) Receivables Turnover : 0.00 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Citius Oncology's Revenue for the six months ended in Sep. 2024 was $0.00 Mil. Citius Oncology's average Accounts Receivable for the six months ended in Sep. 2024 was $0.00 Mil.

Citius Oncology Receivables Turnover Historical Data

The historical data trend for Citius Oncology's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Receivables Turnover Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Receivables Turnover
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Receivables Turnover - - -

Competitive Comparison of Citius Oncology's Receivables Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Receivables Turnover falls into.


;
;

Citius Oncology Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Citius Oncology's Receivables Turnover for the fiscal year that ended in Sep. 2024 is calculated as

Receivables Turnover (A: Sep. 2024 )
=Revenue / Average Total Inventories
=Revenue (A: Sep. 2024 ) / ((Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Sep. 2024 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Citius Oncology's Receivables Turnover for the quarter that ended in Sep. 2024 is calculated as

Receivables Turnover (Q: Sep. 2024 )
=Revenue / Average Total Inventories
=Revenue (Q: Sep. 2024 ) / ((Accounts Receivable (Q: Sep. 2023 ) + Accounts Receivable (Q: Sep. 2024 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology  (NAS:CTOR) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Citius Oncology Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Receivables Turnover
Comparable Companies
ETST ASRT MRMD RMTI SCYX CPIX INCR SXTC RSCI INIS ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.